# Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

> **NCT03543969** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 14 (actual)

## Conditions studied

- Melanoma (Skin)
- Skin Cancer
- Skin Melanoma
- Skin Carcinoma

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Binimetinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03543969
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-14
- **Primary completion:** 2024-12-27
- **Final completion:** 2026-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543969, "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03543969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*